Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

IDH-mutant glioma

Studies

Trials grouped by drug. Open a study for its arms and the response, survival, and safety figures a source reports.

33 studies across 15 of 15 drugs. 33 studies are in the file.

ASTX727 (decitabine/cedazuridine)1 study

HMPL-306 (ranosidenib)2 studies

IDH1-VAC (IDH1 R132H Peptide Vaccine)3 studies

  • NOA-16NCT02454634Phase 1Completedn 39
  • STAR-VACCNCT07888647Phase 2Not yet recruitingn 216
  • iVOCALNCT07877415Phase 1Not yet recruitingn 45

Ivosidenib1 study

Niraparib1 study

  • NCT05406700NCT05406700Phase 1Active, not recruitingn 16

Nivolumab1 study

  • NCT03718767NCT03718767Phase 2Active, not recruitingn 62

Olaparib3 studies

Olutasidenib2 studies

Pamiparib + Temozolomide1 study

  • PNOC017NCT03749187Phase 1Active, not recruitingn 78

RT With Or Without Temozolomide (E3F05)1 study

  • NCT00978458NCT00978458Phase 3Active, not recruitingn 540

Safusidenib (AB-218, DS-1001)5 studies

  • J201 Phase 2NCT04458272Phase 2Active, not recruitingn 25
  • SIGMANCT05303519Phase 3Recruitingn 365
  • G307NCT07712757Phase 3Not yet recruitingn 140
  • G209NCT07703436Phase 2Recruitingn 40
  • SAFU-G3NCT07832123Phase 2Not yet recruitingn 20

Temozolomide Vs PCV With RT (CODEL)1 study

  • NCT00887146NCT00887146Phase 3Active, not recruitingn 305

Tretinoin (ATRA) + Retifanlimab1 study

Tuvusertib1 study

Vorasidenib9 studies